1. ¹Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA
2. ²Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA

Correspondence: Dr Bruce E. Strober, Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York 10016, USA. E-mail: strober@nyc.rr.com

Abstract

Although effective in the treatment of immunodysregulatory diseases such as psoriasis, targeted immunosuppressive agents may confer risks of both enhanced susceptibility to infection and decreased responsiveness to vaccination. In a recent study, Krueger et al. (this issue) investigated these issues by testing the immune response to both a model antigen and a therapeutic vaccination in psoriasis patients during and after treatment with an LFA-1 inhibitor, efalizumab.